Clinical trial
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in…
NCT00289185 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00289185 |
|---|---|
| Title | Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants |
| Official title | A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malaria, Malaria Vaccines |
| Intervention type | Biological |
| Interventions | RTS, S/AS02D, Engerix-B®, TETRActHib™ |
| Enrollment | 340 |
| Start date | Sep 27, 2006 |
| Primary completion | Feb 11, 2008 |
| Completion | Jan 15, 2009 |
| First posted | Feb 9, 2006 |
| Last update posted | Oct 29, 2020 |
| Countries | Tanzania |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: